Sera Prognostics Announces Q4 and Fiscal Year 2025 Financial Results Call

The pregnancy biotech company will host a conference call and webcast on March 18, 2026 to discuss its latest financial performance.

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Sera Prognostics Inc., a leading health diagnostics company focused on improving maternal and neonatal health, announced it will report its fourth quarter and fiscal year 2025 financial results on Wednesday, March 18, 2026, after the market close. The company will host a conference call and live webcast the same day at 5:00 p.m. Eastern Time to discuss operational highlights, financial results, and other key topics.

Why it matters

Sera Prognostics is a prominent player in the pregnancy biotech space, known for its PreTRM test that predicts the risk of spontaneous preterm birth. The company's financial performance and strategic updates are closely watched by investors and the broader maternal health community as indicators of the commercial traction and future growth potential of its innovative diagnostic solutions.

The details

The conference call and webcast will provide Sera Prognostics an opportunity to share details on its Q4 and full-year 2025 financial results, including revenue, profitability, and other key metrics. The company will also likely discuss operational highlights, such as progress on product development, regulatory approvals, reimbursement coverage, and commercial expansion efforts for the PreTRM test and other pipeline offerings.

  • Sera Prognostics will report Q4 and fiscal year 2025 financial results on Wednesday, March 18, 2026, after the market close.
  • The company will host a conference call and live webcast on the same day at 5:00 p.m. Eastern Time.

The players

Sera Prognostics Inc.

A leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care.

PreTRM Test

Sera's flagship product, a blood-based biomarker test that provides an early, accurate, and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies.

Got photos? Submit your photos here. ›

What’s next

Investors and analysts will be closely watching the upcoming conference call and webcast for updates on Sera Prognostics' financial performance, product pipeline, and strategic priorities.

The takeaway

As a leading innovator in the pregnancy biotech space, Sera Prognostics' financial results and operational updates provide valuable insights into the company's progress in developing and commercializing advanced diagnostic solutions to improve maternal and neonatal health outcomes.